6-MAPB: Complete Benzofuran Pharmacology, Metabolism & Safety Monograph

6-MAPB: Complete Benzofuran Pharmacology, Metabolism & Safety Monograph

Evidence warning: 6-MAPB has meaningful receptor, transporter, metabolism, and product-identification evidence, but its direct human clinical literature remains sparse. This page separates confirmed 6-MAPB findings from 5-MAPB, 6-APB, MDMA, and mixed-product evidence.

Emergency stimulant/entactogen toxicity: Seizure, dangerous overheating, severe agitation/confusion, chest pain, collapse, severe muscle rigidity/clonus, very fast/irregular heartbeat, or loss of consciousness after an unknown "Molly"/entactogen product requires urgent medical care.

Quick answer

6-MAPB is 1-(benzofuran-6-yl)-N-methylpropan-2-amine, the N-methyl analogue of 6-APB and a benzofuran entactogen/stimulant related pharmacologically to MDMA-like monoamine drugs.

What is well established:

• the molecule's identity;
• serotonin/dopamine/norepinephrine pharmacology;
• human-liver metabolic pathways;
• conversion to 6-APB as an N-demethyl metabolite;
• forensic methods that distinguish it from related isomers;
• real-world presence in products sold as "Molly."

What remains poorly established:

• controlled human pharmacokinetics;
• isolated 6-MAPB intoxication severity;
• fatality risk;
• dependence incidence;
• withdrawal timeline;
• chronic cardiac/neuropsychiatric outcomes.

Identity

History and market emergence

6-MAPB emerged in the modern NPS market in the early 2010s as part of a benzofuran wave that included:

• 5-APB;
• 6-APB;
• 5-MAPB;
• APDB/MAPDB analogues.

It was encountered in forensic and law-enforcement settings by 2013-2014.

The market context matters because benzofuran products were frequently sold under vague names such as:

• "benzofury";
• "Molly";
• "ecstasy";
• research-chemical labels.

These labels do not reliably establish chemical identity.

Pharmacology

Monoamine transporters

6-MAPB affects the same broad signaling systems involved in MDMA-like entactogenic stimulation:

• serotonin;
• norepinephrine;
• dopamine.

Experimental work supports:

• monoamine uptake inhibition;
• monoamine-releasing/substrate-like behavior;
• high receptor/transporter binding affinity.

Serotonin receptors

A receptor-binding study found 6-MAPB had high affinity across serotonergic targets and significant agonist activity at 5-HT2C.

The broader benzofuran family can also interact with 5-HT2A/2B receptors, but exact functional activity differs by molecule.

This is why 5-APB receptor data should not simply be copied to 6-MAPB.

Relationship to MDMA

6-MAPB is chemically related to MDMA-like entactogens but is not MDMA.

Potential similarities include:

• monoamine release;
• empathogenic/stimulant effects;
• cardiovascular activation;
• serotonergic toxicity risk.

Potential differences include:

• transporter selectivity;
• receptor agonism;
• metabolism;
• duration;
• potency.

No controlled human study establishes a reliable MDMA-equivalence ratio.

Counterfeit "Molly" and the Wesleyan cases

One of the most important real-world 6-MAPB findings came from the Wesleyan University drug-distribution investigation.

A capsule retained from the supply network and later tested by law enforcement contained:

• 6-MAPB;
• AB-FUBINACA, a potent synthetic cannabinoid;

and did not contain MDMA despite being sold as "Molly."

Multiple students became ill in the broader Wesleyan distribution episode, and later in February 2015 11 people overdosed on a substance they believed was Molly; two were critically ill and one reportedly required resuscitation after cardiac arrest.

What this evidence does and does not prove

It proves:

• 6-MAPB circulated in a counterfeit-Molly supply;
• the same product context included a potent synthetic cannabinoid;
• consumer identity assumptions were dangerously wrong.

It does not prove:

• 6-MAPB alone caused the severe clinical outcomes;
• the February 2015 capsules had exactly the same composition as the preserved earlier capsule;
• a specific 6-MAPB concentration caused cardiac arrest.

AB-FUBINACA and potentially other product variation create major confounding.

Acute toxicity: direct vs class evidence

Direct 6-MAPB human evidence

Clean analytically confirmed 6-MAPB-only clinical case series are scarce.

Pharmacologically plausible/class-supported effects

Benzofuran entactogen/stimulant toxicity can include:

• tachycardia;
• hypertension;
• agitation;
• anxiety/panic;
• hyperthermia;
• insomnia;
• jaw/muscle tension;
• confusion;
• serotonergic toxicity;
• seizures in severe cases.

These should be presented as credible class risks, not measured 6-MAPB incidence rates.

Serotonin toxicity

Because 6-MAPB substantially alters serotonergic signaling, serotonin toxicity is a legitimate concern, particularly with other serotonergic drugs.

Features can include:

• agitation;
• hyperthermia;
• clonus/hyperreflexia;
• autonomic instability;
• confusion.

No controlled study defines the risk for any particular combination.

Cardiovascular risk

Possible stimulant/entactogen effects include:

• increased heart rate;
• increased blood pressure;
• palpitations;
• arrhythmia risk.

No prospective human 6-MAPB cardiovascular study establishes a safe exposure or risk threshold.

Interactions

No controlled interaction trials establish safe combinations.

Highest-concern contexts include:

• MAO inhibitors;
• serotonergic stimulants/entactogens;
• other sympathomimetics;
• alcohol/sedatives;
• products containing synthetic cannabinoids or other unknown NPS.

The Wesleyan capsule demonstrates that unexpected cross-class mixtures are not hypothetical.

Metabolism

The 2015 Welter study mapped 6-MAPB metabolism using human liver preparations and analytical systems.

Important pathways include:

• N-demethylation to 6-APB;
• aromatic hydroxylation;
• further oxidative metabolism;
• conjugation.

A major additional metabolite described was 4-carboxymethyl-3-hydroxy methamphetamine.

CYP enzymes

N-demethylation involved:

• CYP1A2;
• CYP2D6;
• CYP3A4.

That creates plausible interaction potential with enzyme inhibitors/inducers, but human clinical effect sizes have not been established.

6-APB as a metabolite

6-APB can appear after 6-MAPB exposure.

This has a major forensic implication:

Detecting 6-APB does not always prove 6-APB was directly ingested if 6-MAPB was also present or otherwise plausible.

Parent/metabolite context matters.

Pharmacokinetics

No controlled human study establishes a universal:

• bioavailability;
• time to peak;
• terminal half-life;
• clearance;
• exposure-response;
• accumulation curve.

Internet duration claims are not equivalent to measured human PK.

Drug testing

Routine screens

Routine amphetamine/MDMA immunoassays cannot be assumed to identify 6-MAPB specifically.

Cross-reactivity can vary.

A routine "amphetamine" or "ecstasy" result does not prove the precise benzofuran present.

Definitive testing

Published methods include:

• GC-MS;
• LC-MS/MS;
• LC-HRMS/MS;
• retention-time/reference-standard comparison.

Isomer differentiation

6-MAPB vs 5-MAPB

The 2015 metabolism study demonstrated chromatographic differentiation from the 5-isomer.

6-MAPB vs 2-MAPB

A 2017 study showed ordinary GC/MS can be ambiguous for 2-MAPB versus 6-MAPB, while tandem-MS approaches can distinguish them more reliably.

Why it matters

Incorrect isomer assignment can distort:

• prevalence;
• clinical case counts;
• metabolism assumptions;
• legal interpretation.

Product identity

A product sold as:

• MDMA;
• Molly;
• 6-MAPB;
• benzofury

may contain another compound or mixture.

No visual inspection or seller label can establish molecular identity.

Tolerance

Repeated monoaminergic psychedelic/stimulant exposure can produce tolerance to some subjective effects.

No human 6-MAPB-specific tolerance study establishes:

• onset;
• magnitude;
• cross-tolerance with MDMA/6-APB/5-MAPB.

Tolerance to subjective effects does not imply equal protection from hyperthermia, cardiovascular stress, serotonergic toxicity, or psychiatric harm.

Dependence and problematic use

6-MAPB-specific epidemiology is absent.

Its monoaminergic stimulant/entactogen pharmacology supports plausible:

• craving;
• repeated redosing;
• binge use;
• compulsive patterns.

The exact incidence of substance use disorder is not established.

Withdrawal / post-use syndrome

No validated 6-MAPB withdrawal timeline exists.

After repeated stimulant/entactogen exposure, possible symptoms can include:

• fatigue;
• depressed mood;
• anhedonia;
• sleep disturbance;
• irritability;
• craving.

These are class-supported concerns, not a proven 6-MAPB syndrome.

Severe depression, suicidality, or persistent psychosis requires medical attention.

Treatment and support

There is no medication approved specifically for 6-MAPB use disorder.

When repeated use becomes compulsive, stimulant-use-disorder treatment principles are reasonable.

Evidence-based behavioral treatment can include:

• contingency management;
• cognitive behavioral approaches;
• community reinforcement.

Acute severe intoxication is treated according to the clinical complications rather than a molecule-specific antidote.

Forensic interpretation

6-APB can be a metabolite

Finding both 6-MAPB and 6-APB may reflect 6-MAPB metabolism rather than two intentionally consumed drugs.

Mixed-product cases require restraint

The Wesleyan evidence cannot be used to assign every symptom to 6-MAPB because AB-FUBINACA was also present in the chemically characterized capsule.

No fatal concentration

There is no validated 6-MAPB fatal blood concentration or impairment threshold.

Special populations

No controlled 6-MAPB safety studies establish risk in:

• pregnancy/breastfeeding;
• adolescents;
• cardiovascular disease;
• seizure disorders;
• bipolar/psychotic disorders;
• liver/kidney impairment.

Missing evidence should not be treated as safety.

Legal status — dated October 3, 2026

United States

The federal schedules reviewed for this monograph do not list 6-MAPB by name as a separately scheduled substance.

Federal authorities have nevertheless described 6-MAPB as an analogue of MDMA in the Wesleyan criminal cases.

Under the federal Controlled Substance Analogue Act, substances meeting statutory criteria and intended for human consumption can be treated as Schedule I controlled substances for federal-law purposes.

This is fact-specific legal territory, not individualized legal advice.

International

This review did not identify a UN convention scheduling decision specifically placing 6-MAPB under international control.

Individual countries—including some European and Commonwealth jurisdictions—control it through named or generic/analogue legislation.

Myths and misconceptions

"6-MAPB is basically MDMA."
Not established. Similar monoamine systems do not create a dose or safety equivalence.

"The Wesleyan overdoses prove 6-MAPB alone caused cardiac arrest."
No. The chemically characterized capsule also contained AB-FUBINACA, and product composition across events was not proven identical.

"If 6-APB is detected, the person definitely took 6-APB."
Not necessarily; 6-APB is an N-demethyl metabolite of 6-MAPB.

"A routine MDMA screen identifies 6-MAPB."
Not reliably or specifically.

"No large clinical literature means it is safer than MDMA."
False. It means the human evidence base is sparse.

Evidence ledger

Related evidence

• 5-APB
• 5-MAPB
• 6-APB
• Benzofurans & entactogens hub
• Substance Use, Dependence & Harm Reduction hub

Bottom line

6-MAPB is a good example of why a serious NPS database has to separate chemistry, human evidence, mixed-product outbreaks, and class inference.

We know the molecule's monoamine pharmacology and metabolism well enough to explain what it is.

We do not have the controlled human data needed to publish a precise dose, half-life, or safety comparison with MDMA.

And the real-world counterfeit-Molly history shows why identity uncertainty itself is part of the toxicity story.